Cargando…

Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome

SIMPLE SUMMARY: For the last 20 years, measurable residual disease (MRD) has proven to be a strong prognostic factor in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, the effects of therapy on the bone marrow (BM) microenvironment and their potential relationship with MRD and pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oliveira, Elen, Costa, Elaine S., Ciudad, Juana, Gaipa, Giuseppe, Sedek, Łukasz, Barrena, Susana, Szczepanski, Tomasz, Buracchi, Chiara, Silvestri, Daniela, Siqueira, Patrícia F. R., Mello, Fabiana V., Torres, Rafael C., Oliveira, Leonardo M. R., Fay-Neves, Isabelle V. C., Sonneveld, Edwin, van der Velden, Vincent H. J., Mejstrikova, Esther, Ribera, Josep-Maria, Conter, Valentino, Schrappe, Martin, van Dongen, Jacques J. M., Land, Marcelo G. P., Orfao, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265080/ https://www.ncbi.nlm.nih.gov/pubmed/35804860 http://dx.doi.org/10.3390/cancers14133088

Ejemplares similares

Flow cytometric minimal residual disease assessment in B‐cell precursor acute lymphoblastic leukaemia patients treated with CD19‐targeted therapies — a EuroFlow study
por: Verbeek, Martijn W. C., et al.
Publicado: (2021)

Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study
por: Lhermitte, Ludovic, et al.
Publicado: (2020)

Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels
por: Sędek, Łukasz, et al.
Publicado: (2022)

Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia
por: Lhermitte, L, et al.
Publicado: (2018)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

Altered neutrophil immunophenotypes in childhood B-cell precursor acute lymphoblastic leukemia
por: Oliveira, Elen, et al.
Publicado: (2016)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
por: Kalina, T, et al.
Publicado: (2012)

Highly sensitive MRD tests for ALL based on the IKZF1 Δ3–6 microdeletion
por: Venn, N C, et al.
Publicado: (2012)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
por: van Dongen, J J M, et al.
Publicado: (2012)

Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia
por: Bras, Anne E., et al.
Publicado: (2020)

FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD)
por: Lo Nigro, Luca, et al.
Publicado: (2022)

ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia
por: van Outersterp, Inge, et al.
Publicado: (2023)

Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2021)

Patient specific real-time PCR in precision medicine – Validation of IG/TR based MRD assessment in lymphoid leukemia
por: Schilhabel, Anke, et al.
Publicado: (2023)

Low PKCa expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome
por: Milani, Gloria, et al.
Publicado: (2014)

BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy
por: Cario, Gunnar, et al.
Publicado: (2020)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

P1361: SLEEPING BEAUTY PLATFORM FOR ENGINEERING CAR-CIK CELLS TOWARD A MULTI-TARGETING STRATEGY IN B-ALL
por: Moretti, Alex, et al.
Publicado: (2023)

Machine Learning Based Analysis of Relations between Antigen Expression and Genetic Aberrations in Childhood B-Cell Precursor Acute Lymphoblastic Leukaemia
por: Kulis, Jan, et al.
Publicado: (2022)

NP-MRD: the Natural Products Magnetic Resonance Database
por: Wishart, David S, et al.
Publicado: (2021)

Flow cytometric immunobead assay for fast and easy detection of PML–RARA fusion proteins for the diagnosis of acute promyelocytic leukemia
por: Dekking, E H A, et al.
Publicado: (2012)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
por: Shiomi, Daisuke, et al.
Publicado: (2013)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)

EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine
por: van Dongen, J J M, et al.
Publicado: (2012)

Mandibular Repositioning Device (MRD) and Obstructive Sleep Apnea Syndrome
por: Nicolaou, Zoe
Publicado: (2019)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
por: Coffey, David G., et al.
Publicado: (2023)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
por: van der Linde, Riana, et al.
Publicado: (2023)

Commonly Assessed Markers in Childhood BCP-ALL Diagnostic Panels and Their Association with Genetic Aberrations and Outcome Prediction
por: Kulis, Jan, et al.
Publicado: (2022)

Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study
por: Brouwer, Nienke, et al.
Publicado: (2022)

Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study
por: van der Velden, Vincent H. J., et al.
Publicado: (2021)

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)
por: Nagafuji, Koji, et al.
Publicado: (2013)

A Cost Impact Analysis of clonoSEQ(®) as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany
por: Walzer, Stefan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4vcnuh05k3oerr046r5j85h38l